vs
indie Semiconductor, Inc.（INDI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
indie Semiconductor, Inc.的季度营收约是REGENXBIO Inc.的1.9倍（$58.0M vs $30.3M），indie Semiconductor, Inc.净利率更高（-53.8% vs -221.3%，领先167.5%），REGENXBIO Inc.同比增速更快（43.0% vs -0.0%），indie Semiconductor, Inc.自由现金流更多（$-16.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 5.3%）
indie Semiconductor是一家无晶圆厂半导体企业，专注于设计高性能混合信号及嵌入式片上系统解决方案，核心面向汽车领域，产品覆盖高级驾驶辅助、车载信息娱乐、车联网及电动汽车场景，服务全球汽车整车厂商及一级供应商。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
INDI vs RGNX — 直观对比
营收规模更大
INDI
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出43.0%
-0.0%
净利率更高
INDI
高出167.5%
-221.3%
自由现金流更多
INDI
多$36.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $58.0M | $30.3M |
| 净利润 | $-31.2M | $-67.1M |
| 毛利率 | 37.3% | — |
| 营业利润率 | -58.5% | -190.0% |
| 净利率 | -53.8% | -221.3% |
| 营收同比 | -0.0% | 43.0% |
| 净利润同比 | 9.1% | -31.2% |
| 每股收益（稀释后） | $-0.16 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDIRGNX
| Q4 25 | $58.0M | $30.3M | ||
| Q3 25 | $53.7M | $29.7M | ||
| Q2 25 | $51.6M | $21.4M | ||
| Q1 25 | $54.1M | $89.0M | ||
| Q4 24 | $58.0M | $21.2M | ||
| Q3 24 | $54.0M | $24.2M | ||
| Q2 24 | $52.4M | $22.3M | ||
| Q1 24 | $52.4M | $15.6M |
净利润INDIRGNX
| Q4 25 | $-31.2M | $-67.1M | ||
| Q3 25 | $-38.3M | $-61.9M | ||
| Q2 25 | $-39.0M | $-70.9M | ||
| Q1 25 | $-34.5M | $6.1M | ||
| Q4 24 | $-34.4M | $-51.2M | ||
| Q3 24 | $-49.7M | $-59.6M | ||
| Q2 24 | $-19.2M | $-53.0M | ||
| Q1 24 | $-31.2M | $-63.3M |
毛利率INDIRGNX
| Q4 25 | 37.3% | — | ||
| Q3 25 | 40.1% | — | ||
| Q2 25 | 40.6% | — | ||
| Q1 25 | 41.7% | — | ||
| Q4 24 | 42.6% | 70.2% | ||
| Q3 24 | 39.3% | 48.8% | ||
| Q2 24 | 42.2% | 52.5% | ||
| Q1 24 | 42.5% | 72.6% |
营业利润率INDIRGNX
| Q4 25 | -58.5% | -190.0% | ||
| Q3 25 | -71.4% | -176.3% | ||
| Q2 25 | -83.3% | -296.3% | ||
| Q1 25 | -72.0% | 13.6% | ||
| Q4 24 | -58.4% | -242.1% | ||
| Q3 24 | -92.5% | -256.6% | ||
| Q2 24 | -70.0% | -251.3% | ||
| Q1 24 | -94.8% | -408.8% |
净利率INDIRGNX
| Q4 25 | -53.8% | -221.3% | ||
| Q3 25 | -71.3% | -208.3% | ||
| Q2 25 | -75.6% | -331.8% | ||
| Q1 25 | -63.9% | 6.8% | ||
| Q4 24 | -59.2% | -241.3% | ||
| Q3 24 | -92.1% | -246.3% | ||
| Q2 24 | -36.6% | -237.7% | ||
| Q1 24 | -59.6% | -405.4% |
每股收益（稀释后）INDIRGNX
| Q4 25 | $-0.16 | $-1.30 | ||
| Q3 25 | $-0.19 | $-1.20 | ||
| Q2 25 | $-0.20 | $-1.38 | ||
| Q1 25 | $-0.18 | $0.12 | ||
| Q4 24 | $-0.18 | $-0.99 | ||
| Q3 24 | $-0.28 | $-1.17 | ||
| Q2 24 | $-0.11 | $-1.05 | ||
| Q1 24 | $-0.19 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.5M | $230.1M |
| 总债务越低越好 | $353.4M | — |
| 股东权益账面价值 | $358.0M | $102.7M |
| 总资产 | $840.8M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.99× | — |
8季度趋势，按日历期对齐
现金及短期投资INDIRGNX
| Q4 25 | $145.5M | $230.1M | ||
| Q3 25 | $160.9M | $274.2M | ||
| Q2 25 | $192.6M | $323.3M | ||
| Q1 25 | $236.6M | $267.9M | ||
| Q4 24 | $274.2M | $234.7M | ||
| Q3 24 | $96.9M | $255.5M | ||
| Q2 24 | $112.3M | $290.4M | ||
| Q1 24 | $138.2M | $338.7M |
总债务INDIRGNX
| Q4 25 | $353.4M | — | ||
| Q3 25 | $353.5M | — | ||
| Q2 25 | $352.5M | — | ||
| Q1 25 | $379.0M | — | ||
| Q4 24 | $381.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益INDIRGNX
| Q4 25 | $358.0M | $102.7M | ||
| Q3 25 | $369.2M | $161.5M | ||
| Q2 25 | $390.4M | $213.7M | ||
| Q1 25 | $405.6M | $274.2M | ||
| Q4 24 | $417.9M | $259.7M | ||
| Q3 24 | $458.6M | $301.4M | ||
| Q2 24 | $470.7M | $348.3M | ||
| Q1 24 | $432.9M | $390.7M |
总资产INDIRGNX
| Q4 25 | $840.8M | $453.0M | ||
| Q3 25 | $855.1M | $525.2M | ||
| Q2 25 | $867.6M | $581.0M | ||
| Q1 25 | $909.0M | $490.9M | ||
| Q4 24 | $941.4M | $466.0M | ||
| Q3 24 | $797.5M | $519.1M | ||
| Q2 24 | $797.3M | $569.4M | ||
| Q1 24 | $803.6M | $629.2M |
负债/权益比INDIRGNX
| Q4 25 | 0.99× | — | ||
| Q3 25 | 0.96× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.93× | — | ||
| Q4 24 | 0.91× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-16.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -27.8% | -174.0% |
| 资本支出强度资本支出/营收 | 3.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-71.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流INDIRGNX
| Q4 25 | $-14.4M | $-52.3M | ||
| Q3 25 | $-6.2M | $-56.0M | ||
| Q2 25 | $-7.6M | $-49.3M | ||
| Q1 25 | $-29.0M | $33.6M | ||
| Q4 24 | $-6.7M | $-31.6M | ||
| Q3 24 | $-22.8M | $-40.5M | ||
| Q2 24 | $-19.7M | $-45.5M | ||
| Q1 24 | $-9.3M | $-55.5M |
自由现金流INDIRGNX
| Q4 25 | $-16.1M | $-52.8M | ||
| Q3 25 | $-10.3M | $-56.5M | ||
| Q2 25 | $-13.6M | $-49.7M | ||
| Q1 25 | $-31.4M | $32.6M | ||
| Q4 24 | $-8.6M | $-32.7M | ||
| Q3 24 | $-29.3M | $-40.9M | ||
| Q2 24 | $-23.4M | $-46.0M | ||
| Q1 24 | $-11.7M | $-56.0M |
自由现金流率INDIRGNX
| Q4 25 | -27.8% | -174.0% | ||
| Q3 25 | -19.2% | -189.9% | ||
| Q2 25 | -26.4% | -232.8% | ||
| Q1 25 | -58.0% | 36.6% | ||
| Q4 24 | -14.8% | -154.2% | ||
| Q3 24 | -54.3% | -168.9% | ||
| Q2 24 | -44.7% | -206.2% | ||
| Q1 24 | -22.3% | -358.5% |
资本支出强度INDIRGNX
| Q4 25 | 3.0% | 1.7% | ||
| Q3 25 | 7.8% | 1.7% | ||
| Q2 25 | 11.6% | 1.8% | ||
| Q1 25 | 4.4% | 1.2% | ||
| Q4 24 | 3.2% | 5.1% | ||
| Q3 24 | 12.1% | 1.3% | ||
| Q2 24 | 7.0% | 2.1% | ||
| Q1 24 | 4.4% | 3.6% |
现金转化率INDIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDI
| Products | $55.7M | 96% |
| Services | $2.3M | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
